Bioavailability of Orally Delivered Alpha- tocopherol by Poly(Lactic-Co-Glycolic) Acid (PLGA) Nanoparticles and Chitosan Covered PLGA Nanoparticles in F344 Rats by Lacey C. Simon et al.
ARTICLE
Nanobiomedicine
Bioavailability of Orally Delivered Alpha-
tocopherol by Poly(Lactic-Co-Glycolic)
Acid (PLGA) Nanoparticles and Chitosan
Covered PLGA Nanoparticles in F344 Rats
Original Research Article
Lacey C. Simon1, Rhett W. Stout2 and Cristina Sabliov1*
1 Department of Biological and Agricultural Engineering, Louisiana State University A&M and LSU Agricultural Center, USA
2 Department of Pathobiological Sciences, Louisiana State University A&M, USA
*Corresponding author(s) E-mail: csabliov@lsu.edu
Received 18 February 2016; Accepted 24 March 2016
DOI: 10.5772/63305
© 2016 Author(s). Licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Abstract
It is hypothesized that the bioavailability of αT (alpha-
tocopherol), an antioxidant, can be improved when
delivered by poly(lactic-co-glycolic) acid (PLGA) nanopar‐
ticles (NPs) and chitosan covered PLGA nanoparticles
(PLGA-Chi NPs), and that the mucoadhesive properties of
chitosan may enhance absorption of αT. PLGA and PLGA-
Chi NPs were characterized by measuring entrapment
efficiency, size, polydispersity, and zeta potential. Nano‐
particle physical stability, chemical stability of entrapped
αT, and release kinetics were also measured. Pharmacoki‐
netic studies were conducted by administering PLGA (αT)
NPs, PLGA-Chi (αT) NPs, and free αT via oral gavage in
rats. The size and zeta potential of the two particle systems
were 97.87 ± 2.63 nm and -36.2 ± 1.31 mV for PLGA(αT) NPs,
and 134 ± 2.05 nm and 38.0 ± 2.90 mV for PLGA-Chi (αT)
nanoparticles in DI water. The particle systems showed to
be stable during various in vitro assays. Bioavailability of
nanodelivered αT was improved compared to the free αT,
by 170% and 121% for PLGA and PLGA-Chi NPs, respec‐
tively. It was concluded that while chitosan did not further
improved bioavailability of αT, PLGA NPs protected the
entrapped drug from the GI environment degradation and
proved to be an effective delivery system for αT.
Keywords Alpha-tocopherol, Bioavailability, PLGA,
Chitosan, Nanodelivery
1. Introduction
Αlpha-tocopherol (αT), a free radical chain-breaking
antioxidant, is the most bioactive form of vitamin E. When
consumed by humans, it has been shown to provide
numerous health benefits [29]. It faces the same challenges
as other orally delivered lipophilic antioxidants including
poor solubility in water, oxidative instability when exposed
to heat, light, and oxygen, chemical and enzymatic insta‐
bility in the gastro-intestinal (GI) tract, and low mucosal
permeability [13; 22; 8]. In addition, the absorption,
transport and distribution of αT is linked to dietary fat.
Absorption in the intestine requires the presence of bile
salts, pancreatic enzymes and adequate fat. Once vitamin
E is internalized into the enterocyte, it is packaged into
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chylomicrons and enters the circulation via the lymphatic
system. Once the chylomicrons are in circulation, their
triglycerides are subjected to hydrolysis via lipoprotein
lipase, which results in the transfer of lipids, including αT,
to peripheral tissues [19]. Because of the connection
between dietary fat and αT absorption, the bioavailability
of αT is highly variable. Bioavailability, as defined by the
FDA, is the rate and extent to which the active drug
ingredient or therapeutic moiety is absorbed and becomes
available at the site of action [13].
To address the variable, often low, bioavailability of αT,
researchers have attempted different ways to improve its
uptake by entrapping it into delivery systems. Nanoparti‐
cles (NPs) have a plethora of advantages over other
delivery systems including the ability to protect drugs from
GI degradation, prolong systemic circulation, reduce fed/
fasted variable absorption, and control the drug’s release
[14]. It is therefore expected that with all the aforemen‐
tioned advantages, bioavailability of orally delivered drugs
in nanoform will be improved. PEGylated NPs have been
developed for drug delivery [11; 3] and several studies have
indicated that poly (lactic-co-glycolic) acid (PLGA) NPs
have improved the bioavailability of drugs compared to
their free form, such as cyclosporine (119% of free form)
[16], estradiol (1014%) [20], doxorubicin (363%) [14],
amphotericin B (793%) [14], curcumin (2583%) [14],
(2200%) [33], (1560%) [17], and lutein [12].
Two mechanisms are proposed for improved bioavailabili‐
ty of nanodelivered drugs, expressed as the area under the
curve (AUC) when plotting the concentration of the drug in
the plasma as a function of time. Either the drug is transport‐
ed within NPs as they are transcytosed, or the particles
release the load in a controlled manner in the intestine, where
it is efficiently absorbed. It is suggested that orally adminis‐
tered  NPs  travel  through  the  GI  tract  where  they  are
absorbed by endocytosis, or by lymphoid uptake, in the M-
cells in the Peyer’s patches [20]. Alternatively, the NPs may
adhere to the M-cells and release only the entrapped drug
into the cell. Mucoadhesive NPs are believed to improve the
bioavailability of  poorly absorbed drugs because of  the
strong attraction of the particles to the negatively charged
mucosa of the intestine responsible for a longer residence
time in the intestine [26]. Chitosan is a non-toxic biopoly‐
mer produced from the deacetylation of chitin, a compo‐
nent  in  crustaceans  and  fungi.  It  has  recently  become
popular in the food and pharmaceutical industries for its
beneficial characteristics including mucoadhesive proper‐
ties, biocompatibility and biodegradability [4]. Chitosan can
be used to confer a positive charge to PLGA NPs when
deposited on the surface of the particles via electrostatic
interaction,  to  form  a  mucoadhesive  PLGA-chitosan
(PLGA-Chi)  NP [22;  2;  32].  One study showed a  228%
increase in AUC when NPs made of PLA (polylactic acid)
coated with chitosan were delivered to rats (Ishak et al.,
2013).
The goal of this study was to determine: if PLGA and
PLGA-Chi NPs improved the bioavailability of lipophilic
antioxidants (αT) by reducing the variable absorption
associated with differences in fat intake; and if the mu‐
coadhesive properties of chitosan improved this bioavail‐
ability even more than PLGA NPs. It was hypothesized that
PLGA and PLGA-Chi NPs improved the bioavailability of
entrapped αT compared to free αT and, further, it was
hypothesized that the mucoadhesive properties of PLGA-
Chi increased the bioavailability of entrapped αT com‐
pared to αT delivered in PLGA NPs. To test the hypotheses,
PLGA and PLGA-Chi NPs were orally administered to
F344 rats and the pharmacokinetic profiles of the NP-
delivered treatment compared to that of the control, or free
αT. To explain the observed pharmacokinetic profile of the
NP-delivered αT better, the release kinetics of αT from both
NP systems were studied. In addition, the physical stability
of the NPs and the chemical stability of the entrapped αT
were examined under GI conditions.
2. Methods
2.1 Materials
Poly (D,l-lactide-co-glycolide) (50:50) with a molecular
weight of 30,000-60,000 Da, Polyvinyl alcohol (PVA)
(31,000-50000 Da), (±)-α-tocopherol (96%) and D-(+)-
Trehalose dehydrate ≥99% were purchased from Sigma
Aldrich (MO, USA). Chitosan with a molecular weight of
100-300 kDa was purchased from Fisher Scientific (NJ,
USA) and ethyl acetate was obtained from Macron Chem‐
icals (PA, USA). Nanopure water was obtained from
Nanopure Diamond (IA, USA). Acetonitrile and methanol,
HPLC grade, were obtained from EMD Chemicals (MA,
USA). Acetic acid was purchased from Fisher Scientific (NJ,
USA). The gastric media was made up of nanopure water,
pepsin from porcine gastric mucosa (Sigma Aldrich) and
hydrochloric acid purchased from Fisher Scientific with
sodium chloride also purchased from Fisher Scientific (NJ,
USA). The intestinal media was composed of nanopure
water, pancreatin purchased from Sigma Aldrich and
sodium hydroxide and potassium hydrogen phosphate
both from Fisher Scientific. Pasteur pipettes and heparin
tubes were both purchased from Fisher Scientific. Male
F344 rats were purchased from Harlan (IN, USA). Bio-Serv
(NJ, USA) provided both rat feed and corn oil stripped of
tocopherols.
2.2 Nanoparticle synthesis
PLGA and PLGA-Chi particles with entrapped αT were
synthesized by an emulsion evaporation method modified
from Zigoneanu et al. [37]. First, the organic phase was
made of 2.5 w/v% PLGA and αT at a 10 w/w% loading
relative to PLGA mass dissolved in ethyl acetate. The
aqueous phase was formed with 2% polyvinyl alcohol
(PVA) dissolved in ethyl acetate-saturated nanopure water.
The organic phase was then slowly added to 40 ml aqueous
phase at an oil to water ratio of 1:5 v:v under continuous
mixing. After the initial emulsification, the emulsion was
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subjected to three rounds of microfluidization by an
M-110p lab homogenizer (Microfluidics, MA, USA) at
30,000 psi to reduce the size of the droplets. Once the
emulsion was completely formed, the ethyl acetate was
evaporated under vacuum in a rotovapor (Buchi R-124,
Buchi Analytical Inc., DE, USA). To form PLGA-Chi
particles, a 0.01 w/v% chitosan solution was made using
nanopure water spiked with acetic acid, creating an acidic
environment for proper chitosan solubility. The chitosan
solution was added to a PLGA NP sample at a chitosan
concentration of 10 w/w% relative to PLGA and mixed
thoroughly using a magnetic spin bar. The final PLGA and
PLGA-Chi NP suspensions were washed by dialysis with
a 100 kD MWCO membrane suspended in 1.5 l water to
remove the PVA, with water changes every eight hours for
72 hours. Finally, particles were lyophilized for 48 hours in
the presence of trehalose as a cryoprotectant at a trehalose
to particle ratio of 1:1.
2.3 Entrapment efficiency
The entrapment efficiency of αT in lyophilized NPs was
determined by dissolving the powder (trehalose and
particles) in 95:5 (v/v%) acetonitrile:water at a concentra‐
tion of 0.2 mg mL-1. The solution was sonicated for one
minute before incubation for two hours at ambient tem‐
perature. Following incubation, the sample was centri‐
fuged at 30,000 rpm for 15 minutes in an Allegra 64R
centrifuge (Beckman Coulter, Fullerton, CA, USA), then
filtered with a 0.2 µm PVDF syringe filter. An Agilent 1200
HPLC (CA, USA) with a binary pump, autosampler and
reverse-phase C18 Xorbax XDB column (Agilent, CA, USA)
was employed for fluorescent detection of αT at an excita‐
tion and emission of 290 nm and 330 nm, respectively. The
mobile phase involved 1 mL min-1 gradient flow of 10%
water and 90% methanol, increasing to 100% methanol over
eight minutes. The total analysis time was 21 minutes per
injection. 25 µl of the filtered sample was injected by the
autosampler and the area under the curve produced by the
fluorescence detector was automatically integrated by
Agilent Chemstation software Rev: B. 03.01 (317) (CA,
USA).
A calibration curve with concentrations ranging from 6–0.1
µg/ml αT in 95:5 acetonitrile:water was produced to
determine the sample concentration from the AUC. All
linear curves used in this study had a correlation coefficient
of at least > 0.99, and inter- and intra-assay variabilities
were determined by quantifying n=3 replicates at five
different concentrations of αT. The entrapment efficiency
was determined by dividing the mass of αT per mg of
powder by the theoretical mass of αT/mg powder.
2.4 Nanoparticle morphology, size, PDI, zeta potential
Particle morphology was identified by transmission
electron microscopy (TEM) using a JEOL JEM-1400 (JEOL
USA Inc., Peabody, MA) system. Lyophilized NPs were re-
suspended in DI water, and one droplet of both PLGA and
PLGA-Chi NPs in suspension was placed on a copper grid
of 400 mesh with carbon film. Uranyl acetate (2%) was used
as a stain, and the sample was dried before analysis. Size,
polydispersity index (PDI) and zeta potential were meas‐
ured by dynamic light scattering (DLS) using a Malvern
Zetasizer Nano ZS (Malvern Instruments, Inc., MA, USA).
For analysis, freeze-dried NPs were re-suspended in
deionized water at a concentration of 0.1 mg ml-1. One mL
of the particle suspension was measured in clear disposable
zeta cells at 25 °C. The refraction index and viscosity were
set equal to that specific to the DI water. The mean values
of size, PDI and zeta potential were determined using a
mono-modal distribution.
2.5 Nanoparticle physical stability
The pH stability of the PLGA and PLGA-Chi NPs was
determined using the Malvern Zetasizer Nano ZS. Particles
were suspended in nanopure water that was titrated from
pH 2.5–9 in increments of 0.5 using dilute HCL and NaOH
solutions [22]. The pH progression was designed to mimic
the pH change during GI transit. Size and zeta potential
were determined at each increment of pH 0.5 and one
measurement per 0.5 pH increment was taken for both
PLGA and PLGA-Chi NPs.
2.6 Αlpha-tocopherol chemical stability
The chemical stability of αT was determined by exposing
both PLGA and PLGA-Chi NPs with entrapped αT to
physiological conditions and measuring the remaining αT
present in the media. Specifically, the NPs were suspended
at 3 mg NPs/ml in simulated gastric and intestinal media,
and the suspensions were kept at 37 ºC and 100 rpm. The
simulated gastric media consisted of 3.2 mg/ml pepsin,
0.03M NaCl, and 7ml HCL/l media, all dissolved in
nanopure water at a pH of 1.2. The intestinal media
contained 10 µg/ml pancreatin, 0.05M kH2PO4 and 0.896 g
NaOH/l media, all dissolved in nanopure water at a pH of
6.8. At various time intervals from 0–3 hours (gastric) and
0–72 hours (intestinal), a sample of the suspension was
centrifuged for 90 minutes at 30,000 rpm, and the αT was
extracted from both the pellet (NPs) and the supernatant
(released αT). The amount of αT was determined using the
HPLC method described in the Entrapment Efficiency
section. The sum of the two quantities revealed the total
amount of αT present; this number was compared to the
total amount of αT determined by the entrapment efficien‐
cy at time 0.
2.7 Nanoparticle release kinetics
In vitro release profiles of αT from PLGA and PLGA-Chi NPs
were determined under simulated gastric and intestinal
environments outlined under the Chemical Stability section.
Following preparation of the gastric and intestinal environ‐
ments, PLGA and PLGA-Chi particles were suspended in
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the gastric or intestinal solution at a concentration of 3 mg/ml
and placed in an incubator at 37 °C and 100 rpm. One ml
samples were collected in triplicate at multiple time points
over the course of the experiment, three hours under gastric
and 72 hours under intestinal conditions. Samples were
centrifuged at 30,000 rpm for 90 minutes to separate the
particles. After particle centrifugation, αT was extracted
from the collected particles  as  previously described for
entrapment efficiency measurement.
2.8 Nanoparticle delivery media preparation
To confirm that PLGA and PLGA-Chi NPs effectively
increased the bioavailability of entrapped αT compared to
free αT, all treatments were delivered in the same media.
Since the bioavailability of αT is dependent on the presence
of dietary lipids, a special delivery system was made,
keeping the amount of lipids constant. The delivery vehicle
consisted of a flour-in-water slurry, made up of 300 mg/ml
refined flour, which was combined with corn oil stripped
of αT (Bio-Serv, NJ, USA) at a ratio of 30:70. The NPs or free
αT were dissolved in this slurry before delivery. Each of the
treatments included 1.5 mg αT (entrapped in NPs or in free
form) delivered in the slurry in a one ml dose.
2.9 Experimental animals
All experimental protocols involving animals were ap‐
proved by the Louisiana State University Institutional
Animal Care and Use Committee (Baton Rouge, LA, USA)
and were carried out in accordance with Directive 2010/63/
EU. Male F344 rats (Harlan Laboratories, IN, USA) weigh‐
ing 240 ± 6 g were housed two per cage and acclimated for
one week with access to food and water ad libitum. During
the last four days of the acclimation period and for the
duration of the study, the rats were fed an AIN-93G rodent
diet (Bio-Serv, NJ, USA), which was stripped of all toco‐
pherols. The rats were fasted for 12 hours before treatment
with free access to water, and n=6 rats were gavaged at time
0 for both treatments and control doses. After gavage, the
tocopherol-free feed was replaced and the rats were
allowed unlimited access. During blood collection, the rats
were temporarily anesthetized with isoflurane. Blood was
collected via the retro-orbital plexus over 72 hours after
gavage. Three rats from each group were serially bled at 0,
2, 8, 24, 48 and 72 hours. The remaining three rats in each
group were serially bled at 0, 4, 12, 36 and 72 hours. The
collected blood was transferred to lithium heparin tubes
(Fisher Scientific, NJ, USA) to prevent clotting, and the
plasma was separated from the blood immediately after by
centrifugation at 6,000 rpm for eight minutes at 20 ºC. The
collected plasma was stored at -80 ºC until processing and
analysis.
2.10. Alpha-tocopherol plasma concentration measurement
To determine the αT concentration, 25 µl of plasma was
thawed and spiked with delta-tocopherol (dT) as an
internal standard (IS). The final IS concentration was 0.1 µg/
ml. Acetonitrile was added to the spiked plasma to precip‐
itate the proteins at a 95:5 acetonitrile:plasma ratio. After,
the mixture was sonicated for one minute in 1.5 ml eppen‐
dorf tubes and allowed to sit undisturbed for 2.5 hours. The
samples were then centrifuged at 30,000 rpm for 15 minutes
and the supernatant was filtered through a 0.2 µm PVDF
syringe filter before being subjected to HPLC-MS analysis,
as follows.
Electrospray analysis was completed using an Agilent 1200
liquid chromatograph with autosampler, in sequence with
an Agilent 6210 mass spectrometer. The 6210 is an ESI –
TOF (ElectroSpray Ionization – Time of Flight) instrument.
Separation was accomplished using a Zorbax SB-C18
column (2.1 x 30mm, 3.5-Micron) (Agilent Technologies,
Santa Clara, CA). The injection volume was 10 µl, with a
mobile phase consisting of (A) water with 0.1% formic acid
and (B) methanol with 0.1% formic acid at a flow rate of 0.2
ml/min. The gradient was 90% methanol and 10% water at
time 0, then the methanol was increased to 100% after eight
minutes until the run was over at 21 minutes after injection.
For purpose of data analysis, the following ions were
extracted from the total chromatogram: 429-431 m/z for αT
and 402-403 m/z for dT. Extracting these ions resulted in
peaks that were integrated using the areas for analysis. A
ratio was calculated by the area of the αT divided by the
area of the dT using MassHunter version B.02.00.
The sample data were compared with a calibration curve
prepared by spiking blank plasma samples with various
amounts of a stock solution of αT (0.05, 0.1, 0.5, 1.0, and 2.0
µg αT/ml) and a constant concentration of 0.1 µg/ml (final)
dT internal standard (IS). Both inter- and intra-assay
variabilities were determined by quantifying n=3 replicates
at five different concentrations of αT using the HPLC-MS
method described for sample processing.
2.11. Pharmacokinetic analysis
The pharmacokinetic parameters were calculated using
NCSS 9, version 9.0.7 (Kaysville, UT, USA). The trapezoidal
rule was employed to determine the AUC for oral admin‐
istration of both treatments and controls. The area under
the concentration-time curve (AUC) was a means to
quantify the total amount of drug (αT) that reached
systemic circulation. The relative bioavailability used in
this study (F) was defined as the AUC of the drug orally
delivered by a specific system divided by the AUC of the
drug orally delivered in free form. Cmax represented the
maximum concentration of the drug detected in the
plasma, and Tmax was the time at which this occured.
2.12. Statistical analysis
The statistical significance of the data was determined
using SAS® version 9.3 (SAS Institute Inc., NC, USA). A
mixed-model analysis of variance with a random mixed-
4 Nanobiomedicine, 2016, 3:8 | doi: 10.5772/63305
effects procedure was used to estimate the significance of
the all data and the difference between the means was




The entrapment efficiency was determined by comparing
the amount of αT present in the NPs after freeze-drying to
the amount of αT used in the synthesis of the particles. The
amount of αT measured in the PLGA NPs was 25.12 ± 2.6
µg/mg NPs, and the amount measured in the PLGA-Chi
NPs totalled 19.49 ± 0.38 µg/mg NPs. According to the
theoretical values, these measurements confirm a 95.4 ±
9.85% entrapment efficiency in the PLGA NPs and a 77.95
± 1.51% entrapment efficiency in the PLGA-Chi NPs.
3.2 Nanoparticle morphology, size, polydispersity and zeta
potential
The PLGA and PLGA-Chi NPs showed a spherical morphol‐
ogy when visualized by TEM (Figure 1). According to DLS
analysis, the PLGA and PLGA-Chi NPs had an average
diameter of 97.87 ± 2.63 nm and 134.1 ± 2.05 nm and a PDI
of 0.156 and 0.298, respectively (Table 1). The zeta poten‐
tial of freshly made PLGA NPs was -36.2 ±1.31 mV, while
the zeta potential of the PLGA-Chi NPs was 38.0 ±2.90 mV
when suspended in nanopure water at pH=5.5 (Table 1).
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Figure 1. TEM images of PLGA NPs (a) and PLGA-Chi NPs (b)
3.3 Nanoparticle physical stability
The PLGA NPs maintained a constant size (~110 nm) and
a close to neutral zeta potential throughout the pH titration
range (pH=2.5–9), (Figure 2a,Table 1). PLGA-Chi particles
varied more in size and zeta potential than the PLGA NPs
over the same pH range. As the pH increased the zeta
potential of PLGA-Chi NPs fell, approaching neutrality,
while particle size increased from 110 to 140 nm (Figure
2b,Table 1).
3.4 Αlpha-tocopherol chemical stability
The results of the chemical stability experiment revealed no
degradation of αT in the particles during the three hours
they were exposed to the gastric environment. From time
0 to three hours, 100% of the entrapped αT was detected
with both particle types (Figure 3a). Similarly, under
simulated intestinal conditions, both particle types provid‐
ed αT protection from degradation during the analysis time
frame (48 hours) (Figure 3 b).
3.5 Alpha-tocopherol release kinetics
Approximately 5% of the entrapped αT was released at
time 0. Three hours later, no more αT had been released
from either PLGA or PLGA-Chi NPs in gastric media
































































































Figure 2. Change in size and zeta potential of PLGA (αT) NPs (a) and PLGA/










size (nm) 97.82 ± 2.63 110.3 114
zeta (mV) -36.2 ± 1.31 0.35 -1.72
PLGA-Chi
NPs
size (nm) 134.1 ± 2.05 116 138
zeta (mV) 38 ± 2.90 31.8 -0.23
Note: * Data reported based on Figure 2
Table 1. Summary of physical properties including size and zeta potential
of PLGA and PLGA-Chi NPs under DI water and GI conditions
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media, the 95% entrapped αT remained in the PLGA and
PLGA-Chi particles. The release kinetics showed no
differences in behaviour between PLGA and PLGA-Chi






























Figure 4. Percentage of αT released from PLGA and PLGA-Chi NPs in a
simulated gastric environment at0, 1.5 and 3 hours (a) andin a simulated

































Figure 3. Total αT measured when PLGA and PLGA-Chi NPs were exposed
to a simulated gastric environment for three hours (a) and simulated
intestinal environment for 48 hours (b)
3.6 Pharmacokinetic profile
After an acute administration of 1.5 mg αT delivered in
PLGA NPs, PLGA-Chi NPs, and in free form, the concen‐
tration of αT in the plasma was measured over time (Figure
5). Free αT showed a rapid uptake and clearance after
administration. The Cmax was 2.91 µg/ml and occurred at a
Tmax of eight hours following oral gavage. At 12 hours, the
plasma concentration of free αT approached the baseline.
On the other hand, both NP-delivered systems showed a
distinct uptake pattern compared to the free αT. At two
hours after administration, an increase in plasma concen‐
tration was evident, but four hours later the concentration
of αT delivered by both NP systems increased to over 3 µg/
ml (Figure 6). These values stayed constant over the
following eight hours, where the PLGA NP-delivered αT
measured 3.35 µg/ml plasma and the PLGA-Chi NP-
delivered αT measured 3.9 µg/ml plasma 12 hours after
administration (Figure 6). Twenty-four hours after admin‐
istration, the plasma concentration of αT delivered by both
NP systems started to decrease. This continued until the
baseline levels of αT were reached by αT delivered by both






































Figure 5. Plasma alpha-tocopherol concentration (µg/ml) delivered in
PLGA, PLGA-Chi and in free form orally to F344 rats (n=6 per treatment).
Three rats per treatment were bled at 0, 2, 8, 24, 48 and 72 hours while the
remaining rats in each group were bled at 0, 4, 12, 36 and 72 hours. The
concentrations were detected using positive ion mass spectroscopy.
Treatment Tmax (h) Cmax (µg/ml) AUC (µg/h/ml)
Free αT 8 2.91 36.64
PLGA NPs 4-12* 3.81 99.00
PLGA-Chi NPs 12 3.92 80.93
Table 2. The pharmacokinetic parameters of Tmax, Cmax, and AUC were
obtained for both treatments and the control from the plasma concentration-
time curve (Figure 5) using NCSS 9 version 9.0.7 (NCSS, LLC. Kaysville, UT,
USA)
From the plasma concentration-time curve, the AUC was
obtained for each of the three curves (Table 2). These results
indicated that the bioavailability of the treatment delivered
by PLGA was 170% higher than the control. Similarly, the
bioavailability of the bioactive delivered in PLGA-Chi NPs
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improved by 121% compared to the free αT. These values
illustrated that both NP systems significantly improved the
bioavailability of lipophilic bioactives when orally deliv‐
ered in rats, but PLGA-Chi NPs did not improve the
bioavailability compared with PLGA NPs under these
conditions.
4. Discussion
Particle behaviour and the in-vivo fate of nanodelivered
bioactives is not a result of one isolated parameter. Rather,
it is heavily influenced by the interdependence of many
parameters such as NP characteristics (e.g., size, surfactant,
zeta potential), type of bioactive (e.g., hydrophobic or
hydrophilic) and route of exposure (e.g., gastric, intestinal,
blood).
Immediately after freeze-drying, the physical characteris‐
tics of PLGA and PLGA-Chi NPs showed similarities in size
but differences in zeta potential. Specifically, they meas‐
ured 97.87 ± 2.63 nm and 134.1 ± 2.05 nm for PLGA and
PLGA Chi NPs, respectively. In terms of zeta potential,
PLGA NPs were very negatively charged (-36 ± 1.31 mV)
and PLGA-Chi NPs were very positively charged (38 ± 2.9
mV) when suspended in DI water at a pH of approximately
5.5. Although the differences in the particles were apparent
in water, when they were exposed to GI conditions, the
characteristics changed in a way that made both PLGA and
PLGA-Chi NPs more similar than when in DI water. For
example, when the particles were exposed to pH changes
mimicking GI transit, the size in the gastric environment
was 110 nm for PLGA NPs and 116 nm for PLGA-Chi NPs
(Table 1). Under gastric conditions, the zeta potential of the
PLGA NPs became close to neutral (0.345 mV), but the zeta
potential of the PLGA-Chi NPs remained strongly positive
(31.8 mV). On the other hand, the major characteristic
separating the two NP systems when freshly made and
suspended in water—the zeta potential—was no longer a
factor under intestinal conditions. The zeta potentials of
both particle systems reached neutrality, measuring -1.72
mV (PLGA NPs) and -0.229 mV (PLGA-Chi NPs) at an
intestinal pH (Table 1). Therefore, under intestinal condi‐
tions NPs had a neutral zeta potential and a similar size,
116 nm (for PLGA NPs) versus 138 nm (for PLGA-Chi NPs)
(Table 1).
Furthermore, knowledge of stability of the αT entrapped in
the particles when exposed to simulated GI environments
is required to understand the fate of the nanodelivered αT
in vivo, especially when determining its bioavailability. No
difference in protection of αT was demonstrated between
PLGA or PLGA-Chi NPs when particles were exposed to
simulated gastric and intestinal conditions over 48 hours.
Over the time frame of this experiment, it was apparent that
the release was in the early stages of the diffusion phase
and no degradation of the polymer occurred, as supported
by other studies [9; 24]. Αlpha-tocopherol is a non-polar
compound, so its tendency to diffuse from inside the
lipophilic matrix of PLGA into a polar environment is not
likely, explaining the low rate of release observed. It was
apparent that αT was protected by the NP systems in the
simulated GI environments (Figure 3) and no αT was
released from the particles between time 0 and three hours
(gastric) and 0 and 72 hours (intestinal) (Figure 4). From
these findings, it must be concluded that the αT was
transported to the intestinal barrier in an entrapped form
and any improvement in bioavailability should be corre‐
lated to the enhanced transport of αT by the particles rather
than the time release of the bioactive.
In general, the AUC of αT increased for other delivery
systems reported in the literature. For example, when the
AUC of the αT delivered to rats in free and nano-emulsion
systems were compared, the nano-emulsion delivered αT
showed a 143% increase in bioavailability compared to the
control (free) form [15]. The AUC of αT was 18% higher
compared to αT delivered in free form when entrapped in
a calcium-pectinate microparticle system and delivered to
rats [29]. A two-fold increase in αT bioavailability was
achieved in humans when delivered as Gelucire 44/14
product [5].
The PK profile in Figure 5 confirmed that nano-delivery
improved bioavailability of αT by more than 100% (p <0.05)
when delivered with PLGA NPs. Perhaps the pharmaco‐
kinetic profiles of the free αT versus the NP entrapped αT
provide insight as to why the AUC for the NP entrapped
αT was larger. Specifically, the plasma concentration of free
αT reached its maximum eight hours after administration
(Figure 5). At 12 hours after administration, a rapid
decrease in plasma concentration was observed, unlike the
αT delivered in nano form. The PK curve for the αT
delivered in nano form reached its maximum plasma
concentration between four and 12 hours after administra‐
tion. This plasma concentration gradually decreased,
reaching baseline 48 hours after administration. Many
factors can influence absorption and transport of lipophilic
bioactives. Nano-delivery enhances the ability of a com‐
pound to be more easily transported transcellularly and
paracellularly across the epithelial cells, whereas larger
aggregates or microemulsions of the same bioactive might
not be small enough to achieve the same level of transport.
This phenomenon might be the reason we saw a much
larger (over 100%) increase in plasma concentration of αT
when delivered in nano form verses free form (Figure 5). In
contrast to the hypothesis that the mucoadhesive proper‐
ties of chitosan will enhance the uptake of αT, we saw no
statistical difference in AUC between PLGA (αT) and
PLGA-Chi (αT). When looking at the in vitro characteristics
of the two particle systems exposed to simulated GI
environments, it is evident they behave similarly (Table 1).
We might also consider the possibility that any mucoad‐
hesive properties displayed in vivo by the PLGA-Chi NPs
might have been counteracted by the increase in size
compared to PLGA NPs (Table 1).
No statistical difference was found between the PLGA and
PLGA-Chi delivered αT (p > 0.05), in line with results
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published by Navarro et al, showing a similar NP biodis‐
tribution for PLGA and PLGA-Chi NPs in a F344 rat model
[23]. Improved bioavailability of the nanodelivered drug
was seen in other studies using PLGA NPs as a delivery
system for different drugs [20; 17; 16] as well as for αT with
other types of delivery systems [29; 5; 15].
5. Conclusions
The lack of data on orally delivered PLGA NPs presented
an opportunity to investigate the ability of PLGA NPs to
improve bioavailability of a model hydrophobic bioactive
(αT) when delivered orally in rats. In addition, it was an
opportunity to improve PLGA NPs’ ability to transport
drugs by adding chitosan, a mucoadhesive compound, on
the surface of the particles. The results indicated that both
particle systems were able to improve the bioavailability of
the αT by over 100%. However, PLGA-Chi NPs did not
improve the bioavailability of the αT delivered over that
delivered by PLGA NPs. This was likely due to the similar
properties of PLGA and PLGA-Chi NPs under the simu‐
lated intestinal environment, where absorption occurs.
However, through the PK study, the effectiveness of PLGA
NPs to improve bioavailability of an entrapped bioactive
was demonstrated. PLGA NPs were proven eligible as a
delivery system that can protect the bioactive from degra‐
dation by preventing release and maintaining its size
stability in GI conditions. PLGA and PLGA-Chi NPs were
not only efficient drug carriers, but they offered an abun‐
dance of advantages over other delivery systems in
addition to improving bioavailability. Unlike other deliv‐
ery systems, polymeric NPs such as PLGA NPs are capable
of protecting the entrapped drug from the GI environment,
can be tailored to desired release properties and are geared
towards the size-dependent uptake suited to the intestinal
membrane. PLGA NPs are a versatile, practical, and
effective delivery system for hydrophobic bioactives with
poor bioavailability.
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